Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.

Next Previous
X
Search
Trial Profile

A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 respiratory infection; Respiratory distress syndrome
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 Jul 2022 Primary endpoint has been met (Change in plasma IL-6 concentration at day 7) , according to Results presented at the 118th International Conference of the American Thoracic Society
    • 15 Apr 2021 Status changed from recruiting to completed.
    • 26 Oct 2020 Planned End Date changed from 24 Aug 2020 to 24 Apr 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top